KR102688509B1 - [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 - Google Patents

[1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 Download PDF

Info

Publication number
KR102688509B1
KR102688509B1 KR1020207005977A KR20207005977A KR102688509B1 KR 102688509 B1 KR102688509 B1 KR 102688509B1 KR 1020207005977 A KR1020207005977 A KR 1020207005977A KR 20207005977 A KR20207005977 A KR 20207005977A KR 102688509 B1 KR102688509 B1 KR 102688509B1
Authority
KR
South Korea
Prior art keywords
isopropyl
triazolo
indol
piperidin
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005977A
Other languages
English (en)
Korean (ko)
Other versions
KR20200036913A (ko
Inventor
알라릭 제이. 딕맨
트레버 씨. 셔우드
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200036913A publication Critical patent/KR20200036913A/ko
Application granted granted Critical
Publication of KR102688509B1 publication Critical patent/KR102688509B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020207005977A 2017-08-04 2018-08-03 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물 Active KR102688509B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541331P 2017-08-04 2017-08-04
US62/541,331 2017-08-04
PCT/US2018/045080 WO2019028301A1 (en) 2017-08-04 2018-08-03 INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL

Publications (2)

Publication Number Publication Date
KR20200036913A KR20200036913A (ko) 2020-04-07
KR102688509B1 true KR102688509B1 (ko) 2024-07-24

Family

ID=63364163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005977A Active KR102688509B1 (ko) 2017-08-04 2018-08-03 [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물

Country Status (7)

Country Link
US (1) US11130756B2 (https=)
EP (1) EP3661934B1 (https=)
JP (1) JP7266576B2 (https=)
KR (1) KR102688509B1 (https=)
CN (1) CN110997670B (https=)
ES (1) ES2921020T3 (https=)
WO (1) WO2019028301A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo
BR112020012084A2 (pt) 2017-12-19 2020-11-24 Bristol-Myers Squibb Company compostos de indol substituído úteis como inibidores de tlr
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
KR20210018818A (ko) 2018-06-05 2021-02-18 에프. 호프만-라 로슈 아게 자가면역 질환의 치료를 위한 테트라하이드로-1H-피라지노[2,1-a]이소인돌릴퀴놀린 화합물
EP3807270B1 (en) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
US11952363B2 (en) 2018-07-23 2024-04-09 Hoffmann-La Roche Inc. Piperazine compounds for the treatment of autoimmune disease
WO2020048583A1 (en) 2018-09-04 2020-03-12 F. Hoffmann-La Roche Ag Benzothiazole compounds for the treatment of autoimmune diseases
WO2020048595A1 (en) 2018-09-06 2020-03-12 F. Hoffmann-La Roche Ag Novel cyclic amidine compounds for the treatment of autoimmune disease
JP7367004B2 (ja) 2018-09-06 2023-10-23 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のための新規のピラゾロビリジン化合物
US12421240B2 (en) 2019-10-31 2025-09-23 Hoffmann-La Roche Inc. Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
JP2023502087A (ja) 2019-11-19 2023-01-20 エフ．ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのヒドロ－１Ｈ－ピロロ［１，２－ａ］ピラジン化合物
JP7649306B2 (ja) 2019-11-20 2025-03-19 エフ． ホフマン－ラ ロシュ アーゲー 自己免疫疾患の処置のためのスピロ（イソベンゾフラナゼチジン）化合物
AU2021328577A1 (en) 2020-08-19 2023-03-23 Bristol-Myers Squibb Company 1H-pyrrolo[3,2-c]pyridine and 1H-pyrrolo[2,3-c]pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
AR123281A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como inhibidores de tlr9
AR123286A1 (es) 2020-08-19 2022-11-16 Bristol Myers Squibb Co Compuestos de benzimidazol sustituidos útiles como inhibidores de tlr9
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0104987A3 (en) 1998-12-18 2002-09-30 Axys Pharmaceuticals Inc South Benzimidazole or indole derivatives protease inhibitors, and pharmaceutical compositions containing them
MXPA05013922A (es) 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
WO2007115306A2 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
WO2008065198A1 (en) 2006-12-01 2008-06-05 Galapagos N.V. Triazolopyridine compounds useful for the treatment of degenerative & inflammatory diseases
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
CA2709514A1 (en) * 2007-12-21 2009-07-02 Astrazeneca Ab Bicyclic derivatives for use in the treatment of androgen receptor associated conditions
FR2926556B1 (fr) 2008-01-22 2010-02-19 Sanofi Aventis Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique
US8354400B2 (en) 2008-09-26 2013-01-15 Eisai R&D Co., Ltd. Benzoxazole compounds and methods of use
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
NO2453895T3 (https=) 2009-07-16 2018-10-20
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
EP3208263A1 (en) 2011-01-12 2017-08-23 VentiRx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
DK2663555T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
TWI567079B (zh) 2011-07-15 2017-01-21 健生醫藥公司 作為伽瑪分泌酶調節劑之新穎的經取代的吲哚衍生物
CA2850932A1 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
JP6184423B2 (ja) 2012-05-18 2017-08-23 大日本住友製薬株式会社 カルボン酸化合物
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
SG10202103278TA (en) 2013-10-14 2021-04-29 Eisai R&D Man Co Ltd Selectively substituted quinoline compounds
EP3080124A1 (en) * 2013-12-13 2016-10-19 Takeda Pharmaceutical Company Limited Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors
UY35935A (es) * 2014-01-03 2015-06-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Compuestos de nicotinamida sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4
EP3183251A4 (en) 2014-08-22 2017-12-27 Janus Biotherapeutics, Inc. Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
MX391344B (es) 2016-07-30 2025-03-21 Bristol Myers Squibb Co Compuestos indol sustituidos con dimetoxifenilo como inhibidores de receptores tipo toll 7, 8 o 9 (tlr7, tlr8 o tlr9).
KR102519535B1 (ko) 2016-09-09 2023-04-06 브리스톨-마이어스 스큅 컴퍼니 피리딜 치환된 인돌 화합물
US20190192703A1 (en) 2016-09-16 2019-06-27 Nordic Nanovector Asa Treatment of non-hodgkin lymphoma using lilotomab and 177lu-lilotomab satetraxetan
ES2921020T3 (es) 2017-08-04 2022-08-16 Bristol Myers Squibb Co Compuestos de indol sustituidos con [1,2,4]triazolo[4,3-a]piridinilo

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases

Also Published As

Publication number Publication date
US11130756B2 (en) 2021-09-28
EP3661934B1 (en) 2022-06-01
WO2019028301A1 (en) 2019-02-07
US20200369661A1 (en) 2020-11-26
EP3661934A1 (en) 2020-06-10
CN110997670B (zh) 2022-11-01
ES2921020T3 (es) 2022-08-16
JP7266576B2 (ja) 2023-04-28
KR20200036913A (ko) 2020-04-07
CN110997670A (zh) 2020-04-10
JP2020529436A (ja) 2020-10-08

Similar Documents

Publication Publication Date Title
KR102688509B1 (ko) [1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
USRE49931E1 (en) [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR102742181B1 (ko) 6-아자인돌 화합물
KR102651947B1 (ko) Tlr7/8/9의 억제제로서 유용한 치환된 인돌 화합물
KR102714788B1 (ko) Tlr 억제제로서 유용한 아미노 인돌 화합물
KR102781141B1 (ko) 치환된 인돌 에테르 화합물
KR102839382B1 (ko) 치환된 인돌 및 인다졸 화합물
KR20220079587A (ko) 치환된 카르바졸 화합물
KR102904576B1 (ko) 치환된 벤즈이미다졸론 화합물
KR20210080462A (ko) 치환된 인돌 이량체 화합물
BR112018077119B1 (pt) COMPOSTOS INDÓIS SUBSTITUÍDOS COM [1,2,4]TRIAZOL[1,5-a]PIRIDINILA, USO DOS MESMOS, E COMPOSIÇÃO FARMACÊUTICA

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200228

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210803

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230829

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240425

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240722

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240722

End annual number: 3

Start annual number: 1

PG1601 Publication of registration